Los Angeles, CANCT05457283Now EnrollingIRB Ready

Chronic Kidney Disease Clinical Trial in Los Angeles, CA

Access cutting-edge chronic kidney disease treatment through this phase 3 clinical trial at a research site in Los Angeles. Study-provided care at no cost to qualified participants.

Sponsored by Bayer

Quick Self-Assessment

See if you qualify for this Los Angeles location

Preparing your pre-screening questions…

Expert Care in Los Angeles

Access chronic kidney disease specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related chronic kidney disease treatment provided free

Apply for This Los Angeles Location

Check if you qualify for this chronic kidney disease clinical trial in Los Angeles, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Los Angeles

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Los Angeles site if eligible
  4. 4Begin participation

About This Chronic Kidney Disease Study in Los Angeles

Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney disease, and proteinuria, a condition in which a person´s kidneys leak protein into the urine. The kidneys filter waste and fluid from the blood to form urine. In children with CKD, the kidney´s filters do not work as well as they should. This can lead to accumulation of waste and fluid in the body and proteinuria. CKD can lead to other medical problems, such as high blood

Sponsor: Bayer

Who Can Participate

Inclusion Criteria

Participants must be ≥1 year to 18 years of age, at the time of signing the informed consent/assent.
Prior participation in the finerenone Phase 3 study FIONA (19920) and not permanently discontinued from treatment by the end of treatment (EoT) visit in FIONA.
Participants must have a clinical diagnosis of chronic kidney disease (CKD) at Visit 1 which is defined as
CKD stages 1-3 (estimated glomerular filtration rate \[eGFR\] ≥30 mL/min/1.73m\^2) for children ≥1 year to \<19 years of age at FIONA EoT and at Visit 1
Treated with an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) at optimized doses defined as maximally tolerable doses within the recommended dose range according to guidelines on blood pressure (BP) management, unchanged for at least 30 days prior to Visit 1.
K+ ≤5.0 mmol/L for children ≥2 years of age at both FIONA EoT and Visit 1, and ≤5.3 mmol/L for children \<2 years of age at both FIONA EoT and Visit 1
Participants who have reached legal age of consent: Capable of giving signed informed consent.
Participant is able to receive enteral feeding (solid food, bottle or cup fed, feeding through nasogastric or gastric feeding tubes) with or without breastfeeding.

Exclusion Criteria

Planned urological surgery expected to influence renal function
Patients who are candidates for renal transplantation, i.e., a kidney transplantation scheduled within the study time frame
Systemic hypertension Stage 2 defined according to institutional guidelines on BP management at Visit 1.
Systemic hypotension defined as symptomatic hypotension or a mean systolic BP below the 5th percentile for age, sex and height but no lower than 80 mmHg for participants \<18 years and symptomatic hypotension or a mean systolic blood pressure (SBP) \<90 mmHg in participants ≥18 years at Visit 1.
Known hypersensitivity to the study treatment (active substance or excipients)
Severe hepatic insufficiency defined by e.g. Child-Pugh C or analogous scores.
Participants using rituximab, cyclophosphamide, abatacept, or intravenous glucocorticoids
Concomitant therapy with a mineralocorticoid receptor antagonist (MRA)(eplerenone, spironolactone, esaxerenone, canrenone), any renin inhibitor (aliskiren, enalkiren, remikiren), any sodium-glucose co-transporter-2 (SGLT2) inhibitor (SGLT2i), sacubitril/valsartan combination (ARNI), or potassium-sparing diuretic (amiloride, triamterene)
Concomitant therapy with both ACEI and ARBs together
Concomitant therapy with strong cytochrome P450 isoenzyme 3A4 (CYP3A4) inhibitors, moderate or strong CYP3A4 inducers
Previous assignment to treatment during this study
Simultaneous participation in another interventional clinical study (e.g., Phase 1 to 4 clinical studies).
Any suspected (serious) adverse event related to study intervention which led to permanent discontinuation during the FIONA study.
Pregnant or breastfeeding or intention to become pregnant during the study

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Los Angeles?

Yes, this clinical trial (NCT05457283) has an active research site in Los Angeles, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Chronic Kidney Disease Treatment Options in Los Angeles, CA

If you're searching for chronic kidney disease treatment options in Los Angeles, CA, this clinical trial (NCT05457283) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Los Angeles research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced chronic kidney disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all chronic kidney disease clinical trials near you to find additional studies recruiting in your area.

More Ankylosing Spondylitis Trials in Los Angeles, CA

See all ankylosing spondylitis clinical trials recruiting in Los Angeles — not just this study.

Browse Ankylosing Spondylitis Trials in Los Angeles →

Browse More Trials by Condition

Ankylosing Spondylitis TrialsChronic Kidney Disease TrialsInterstitial Cystitis TrialsAll Conditions →

Ready to Join in Los Angeles?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Los Angeles, CA